Skip to main content

SelectQuote, Inc. Reports Fourth Quarter of Fiscal Year 2025 Results

Fourth Quarter of Fiscal Year 2025 – Consolidated Earnings Highlights

  • Revenue of $345.1 million
  • Net income of $12.9 million
  • Adjusted EBITDA* of $2.7 million

Fiscal Year 2026 Guidance Ranges:

  • Revenue expected in a range of $1.650 billion to $1.750 billion
  • Adjusted EBITDA* expected in a range of $120 million to $150 million

Fourth Quarter Fiscal Year 2025 – Segment Highlights

Senior

  • Revenue of $82.5 million
  • Adjusted EBITDA* of $7.7 million
  • Approved Medicare Advantage policies of 85,344

Healthcare Services

  • Revenue of $214.0 million
  • Adjusted EBITDA* of $11.9 million
  • 108,018 SelectRx members

Life

  • Revenue of $48.0 million
  • Adjusted EBITDA* of $6.9 million

SelectQuote, Inc. (NYSE: SLQT) reported consolidated revenue for the fourth quarter of fiscal year 2025 of $345.1 million compared to consolidated revenue for the fourth quarter of fiscal year 2024 of $307.2 million. Consolidated net income for the fourth quarter of fiscal year 2025 was $12.9 million compared to consolidated net loss for the fourth quarter of fiscal year 2024 of $31.0 million. Finally, consolidated Adjusted EBITDA* for the fourth quarter of fiscal year 2025 was $2.7 million compared to consolidated Adjusted EBITDA* for the fourth quarter of fiscal year 2024 of $14.4 million.

Tim Danker, SelectQuote Chief Executive Officer, commented “The strength of our holistic healthcare services model was broadly exhibited in fiscal 2025, and we firmly believe the years ahead will increasingly drive substantial value for each of our stakeholders. Policyholders and patients will continue to benefit from our information advantage through tailored advice and healthcare solutions, which ultimately result in better health outcomes. Our insurance and healthcare service partners benefit from better treatment fit and adherence, which eliminates waste and serves to ease the historical trend of rising healthcare costs for Americans. Additionally, we believe our shareholders will benefit as SelectQuote’s diverse breadth of revenues drive increasing cash flow, which will accelerate and compound with new growth initiatives in the future.”

Mr. Danker continued, “We are proud to have delivered financial results well in excess of our initial expectations for the 3rd consecutive year. Over that period, our Adjusted EBITDA results have outperformed our forecasts by more than 20% each year. Our leadership and workforce have accomplished these results through significant change in Medicare Advantage in each year. We credit the talent and hard work of our people and are exceedingly proud of the track record SelectQuote has built as an agile, innovative and reliable source of value for Americans seeking healthcare that best fits their needs.”

* See “Non-GAAP Financial Measures” below.

Segment Results

We currently have three reportable segments: 1) Senior, 2) Healthcare Services and 3) Life. The performance measures of the segments include total revenue and Adjusted EBITDA.* Costs of commissions and other services revenue, cost of goods sold-pharmacy revenue, marketing and advertising, selling, general, and administrative, and technical development operating expenses that are directly attributable to a segment are reported within the applicable segment. Indirect costs of revenue, marketing and advertising, selling, general, and administrative, and technical development operating expenses are allocated to each segment based on varying metrics such as headcount. Adjusted EBITDA is our segment profit measure to evaluate the operating performance of our business. We define Adjusted EBITDA as income (loss) before income tax expense (benefit) plus: (i) interest expense, net; (ii) depreciation and amortization; (iii) share-based compensation; (iv) goodwill, long-lived asset, and intangible assets impairments; (v) transaction costs; (vi) loss on disposal of property, equipment and software, net; (vii) other non-recurring expenses and income; (viii) changes in fair value of warrant liabilities. Adjusted EBITDA margin is calculated as Adjusted EBITDA divided by revenue.

Senior

Financial Results

The following table provides the financial results for the Senior segment for the periods presented:

 

Three Months Ended June 30,

 

 

 

Year Ended June 30,

 

(in thousands)

 

2025

 

 

 

2024

 

 

% Change

 

 

2025

 

 

 

2024

 

 

% Change

Revenue

$

82,464

 

 

$

114,143

 

 

(28

)%

 

$

600,393

 

 

$

655,849

 

 

(8

)%

Adjusted EBITDA*

 

7,722

 

 

 

27,872

 

 

(72

)%

 

 

161,671

 

 

 

166,744

 

 

(3

)%

Adjusted EBITDA Margin*

 

9

%

 

 

24

%

 

 

 

 

27

%

 

 

25

%

 

 

Operating Metrics

Submitted Policies

Submitted policies are counted when an individual completes an application with our licensed agent and provides authorization to the agent to submit the application to the insurance carrier partner. The applicant may have additional actions to take before the application will be reviewed by the insurance carrier.

The following table shows the number of submitted policies for the periods presented:

 

Three Months Ended June 30,

 

 

 

Year Ended June 30,

 

 

 

2025

 

2024

 

% Change

 

2025

 

2024

 

% Change

Medicare Advantage

85,979

 

117,091

 

(27

)%

 

674,851

 

720,027

 

(6

)%

All other (1)

21,438

 

15,260

 

40

%

 

87,413

 

72,906

 

20

%

Total

107,417

 

132,351

 

(19

)%

 

762,264

 

792,933

 

(4

)%

(1) Represents the submitted policies for Medicare supplement, dental, vision and hearing, prescription drug plan and other.

* See “Non-GAAP Financial Measures” below.

Approved Policies

Approved policies represents the number of submitted policies that were approved by our insurance carrier partners for the identified product during the indicated period. Not all approved policies will go in force.

The following table shows the number of approved policies for the periods presented:

 

Three Months Ended June 30,

 

 

 

Year Ended June 30,

 

 

 

2025

 

2024

 

% Change

 

2025

 

2024

 

% Change

Medicare Advantage

85,344

 

107,272

 

(20

)%

 

592,874

 

625,245

 

(5

)%

All other (1)

19,979

 

13,849

 

44

%

 

70,295

 

62,419

 

13

%

Total

105,323

 

121,121

 

(13

)%

 

663,169

 

687,664

 

(4

)%

(1) Represents the approved policies for medicare supplement, dental, vision and hearing, prescription drug plan and other.

Lifetime Value of Commissions per Approved Policy

Lifetime value of commissions per approved policy represents commissions estimated to be collected over the estimated life of an approved policy based on multiple factors, including but not limited to, contracted commission rates, carrier mix and expected policy persistency with applied constraints. The lifetime value of commissions per approved policy is equal to the sum of the commission revenue due upon the initial sale of a policy, and when applicable, an estimate of future renewal commissions.

The following table shows the lifetime value of commissions per approved policy for the periods presented:

 

Three Months Ended June 30,

 

 

 

Year Ended June 30,

 

 

(dollars per policy):

2025

 

2024

 

% Change

 

2025

 

2024

 

% Change

Medicare Advantage

$

837

 

$

847

 

(1

)%

 

$

884

 

$

910

 

(3

)%

All other (1)

 

125

 

 

186

 

(33

)%

 

 

134

 

 

146

 

(8

)%

(1) Represents the weighted average LTV per approved policy.

Healthcare Services

Financial Results

The following table provides the financial results for the Healthcare Services segment for the periods presented:

 

Three Months Ended June 30,

 

 

 

Year Ended June 30,

 

 

(in thousands)

 

2025

 

 

 

2024

 

 

% Change

 

 

2025

 

 

 

2024

 

 

% Change

Revenue

$

214,028

 

 

$

145,223

 

 

47

%

 

$

742,705

 

 

$

478,508

 

 

55

%

Adjusted EBITDA*

 

11,853

 

 

 

909

 

 

1,204

%

 

 

25,387

 

 

 

7,821

 

 

225

%

Adjusted EBITDA Margin*

 

6

%

 

 

1

%

 

 

 

 

3

%

 

 

2

%

 

 

Operating Metrics

Members

The total number of SelectRx members represents the amount of active customers to which an order has been shipped and the prescriptions per day represents the total average prescriptions shipped per business day. These two metrics are the primary drivers of revenue for Healthcare Services.

* See “Non-GAAP Financial Measures” below.

The following table shows the total number of SelectRx members as of the periods presented:

 

 

June 30, 2025

 

June 30, 2024

Total SelectRx Members

 

108,018

 

82,385

The total number of SelectRx members increased by 31% as of June 30, 2025, compared to June 30, 2024, due to our strategy to grow SelectRx membership.

The following table shows the average prescriptions shipped per day for the periods presented:

 

 

Three Months Ended June 30,

 

Year Ended June 30,

 

 

2025

 

2024

 

2025

 

2024

Prescriptions Per Day

 

30,630

 

22,950

 

27,867

 

18,935

Combined Senior and Healthcare Services - Consumer Per Unit Economics

Combined Senior and Healthcare Services consumer per unit economics represents total MA and MS commissions; other product commissions; other revenues, including revenues from Healthcare Services; and operating expenses associated with Senior and Healthcare Services, each shown per number of approved MA and MS policies over a given time period. Management assesses the business on a per-unit basis to help ensure that the revenue opportunity associated with a successful policy sale is attractive relative to the marketing acquisition cost. Because not all acquired leads result in a successful policy sale, all per-policy metrics are based on approved policies, which is the measure that triggers revenue recognition.

The MA and MS commission per MA/MS policy represents the LTV for policies sold in the period. Other commission per MA/MS policy represents the LTV for other products sold in the period, including DVH prescription drug plan, and other products, which management views as additional commission revenue on our agents’ core function of MA/MS policy sales. Pharmacy revenue per MA/MS policy represents revenue from SelectRx, and other revenue per MA/MS policy represents revenue from Population Health, production bonuses, marketing development funds, lead generation revenue, and adjustments from the Company’s reassessment of its cohorts’ transaction prices. Total operating expenses per MA/MS policy represents all of the operating expenses within Senior and Healthcare Services. The revenue to customer acquisition cost (“CAC”) multiple represents total revenue as a multiple of total marketing acquisition cost, which represents the direct costs of acquiring leads. These costs are included in marketing and advertising expense within the total operating expenses per MA/MS policy.

The following table shows combined Senior and Healthcare Services consumer per unit economics for the periods presented. Based on the seasonality of Senior and the fluctuations between quarters, we believe that the most relevant view of per unit economics is on a rolling 12-month basis. All per MA/MS policy metrics below are based on the sum of approved MA/MS policies, as both products have similar commission profiles.

 

Twelve Months Ended June 30,

(dollars per approved policy):

 

2025

 

 

 

2024

 

MA and MS approved policies

 

594,572

 

 

 

627,130

 

MA and MS commission per MA / MS policy

$

885

 

 

$

910

 

Other commission per MA/MS policy

 

12

 

 

 

12

 

Pharmacy revenue per MA/MS policy

 

1,219

 

 

 

741

 

Other revenue per MA/MS policy

 

86

 

 

 

146

 

Total revenue per MA / MS policy

 

2,202

 

 

 

1,809

 

Total operating expenses per MA / MS policy

 

(1,937

)

 

 

(1,530

)

Adjusted EBITDA per MA/MS policy *

$

265

 

 

$

279

 

Adjusted EBITDA Margin per MA/MS policy *

 

12

%

 

 

15

%

Revenue / CAC multiple

6.1X

 

4.5X

Total revenue per MA/MS policy increased 22% for the twelve months ended June 30, 2025, compared to the twelve months ended June 30, 2024, primarily due to the increase in pharmacy revenue. Total operating expenses per MA/MS policy increased 27% for the twelve months ended June 30, 2025, compared to the twelve months ended June 30, 2024, driven by an increase in cost of goods sold-pharmacy revenue for Healthcare Services due to the growth of the business.

Life

Financial Results

The following table provides the financial results for the Life segment for the periods presented:

 

Three Months Ended June 30,

 

 

 

Year Ended June 30,

 

 

(in thousands)

 

2025

 

 

 

2024

 

 

% Change

 

 

2025

 

 

 

2024

 

 

% Change

Revenue

$

47,984

 

 

$

42,074

 

 

14

%

 

$

172,978

 

 

$

157,930

 

 

10

%

Adjusted EBITDA*

 

6,922

 

 

 

7,217

 

 

(4

)%

 

 

26,669

 

 

 

20,164

 

 

32

%

Adjusted EBITDA Margin*

 

14

%

 

 

17

%

 

 

 

 

15

%

 

 

13

%

 

 

Operating Metrics

Life premium represents the total premium value for all policies that were approved by the relevant insurance carrier partner and for which the policy document was sent to the policyholder and payment information was received by the relevant insurance carrier partner during the indicated period. Because our commissions are earned based on a percentage of total premium, total premium volume for a given period is the key driver of revenue for our Life segment.

The following table shows term and final expense premiums for the periods presented:

 

Three Months Ended June 30,

 

 

 

Year Ended June 30,

 

 

(in thousands)

2025

 

2024

 

% Change

 

2025

 

2024

 

% Change

Term Premiums

$

19,989

 

$

18,074

 

11

%

 

$

71,448

 

$

70,450

 

1

%

Final Expense Premiums

 

30,807

 

 

23,789

 

30

%

 

 

105,099

 

 

86,600

 

21

%

Total

$

50,796

 

$

41,863

 

21

%

 

$

176,547

 

$

157,050

 

12

%

* See “Non-GAAP Financial Measures” below.

Earnings Conference Call

SelectQuote, Inc. will host a conference call with the investment community on August 21, 2025, beginning at 8:30 a.m. ET. To register for this conference call, please use this link: https://registrations.events/direct/Q4I547808. After registering, a confirmation will be sent via email, including dial-in details and unique conference call codes for entry. Registration is open through the live call, but to ensure you are connected for the full call we suggest registering at least 10 minutes before the start of the call. The event will also be webcasted live via our investor relations website https://ir.selectquote.com/investor-home/default.aspx.

Non-GAAP Financial Measures

This release includes certain non-GAAP financial measures intended to supplement, not substitute for, comparable GAAP measures. To supplement our financial statements presented in accordance with GAAP and to provide investors with additional information regarding our GAAP financial results, we have presented in this release Adjusted EBITDA, which is a non-GAAP financial measure. This non-GAAP financial measure is not based on any standardized methodology prescribed by GAAP and is not necessarily comparable to any similarly titled measure presented by other companies. We define Adjusted EBITDA as net income (loss) before income tax expense (benefit), plus interest expense, depreciation and amortization, changes in fair value of warrant liabilities, and certain add-backs for non-cash or non-recurring expenses, including restructuring and share-based compensation expenses. The most directly comparable GAAP measure is net income (loss) before income tax expense (benefit). We monitor and have presented in this release Adjusted EBITDA because it is a key measure used by our management and Board of Directors to understand and evaluate our operating performance, establish budgets, and develop operational goals for managing our business. In particular, we believe that excluding the impact of these expenses in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our core operating performance.

Reconciliations of net income (loss) before income tax expense (benefit) to Adjusted EBITDA are presented below beginning on page 12. The Company is unable to provide a quantitative reconciliation of forward-looking Adjusted EBITDA to its most directly comparable GAAP measure without unreasonable effort because it is not possible to predict certain information included in the calculation of such GAAP measure, including the fair value of outstanding warrants to purchase shares of the Company's common stock. The unavailable information could have a significant impact on the Company's GAAP financial results.

Forward Looking Statements

This release contains forward-looking statements. These forward-looking statements reflect our current views with respect to, among other things, future events and our financial performance. These statements are often, but not always, made through the use of words or phrases such as “may,” “should,” “could,” “predict,” “potential,” “believe,” “will likely result,” “expect,” “continue,” “will,” “anticipate,” “seek,” “estimate,” “intend,” “plan,” “projection,” “would” and “outlook,” or the negative version of those words or other comparable words or phrases of a future or forward-looking nature. These forward-looking statements are not historical facts and are based on current expectations, estimates and projections about our industry, management’s beliefs and certain assumptions made by management, many of which, by their nature, are inherently uncertain and beyond our control. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions and uncertainties that are difficult to predict. Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, actual results may prove to be materially different from the results expressed or implied by the forward-looking statements.

There are or will be important factors that could cause our actual results to differ materially from those indicated in these forward-looking statements, including, but not limited to, the following: our reliance on a limited number of insurance carrier partners and any potential termination of those relationships or failure to develop new relationships; existing and future laws and regulations affecting the health insurance market; changes in health insurance products offered by our insurance carrier partners and the health insurance market generally; insurance carriers offering products and services directly to consumers; changes to commissions paid by insurance carriers and underwriting practices; competition with brokers, exclusively online brokers and carriers who opt to sell policies directly to consumers; competition from government-run health insurance exchanges; developments in the U.S. health insurance system; our dependence on revenue from carriers in our senior segment and downturns in the senior health as well as life, automotive and home insurance industries; our ability to develop new offerings and penetrate new vertical markets; risks from third-party products; failure to enroll individuals during the Medicare annual enrollment period; our ability to attract, integrate and retain qualified personnel; our dependence on lead providers and ability to compete for leads; failure to obtain and/or convert sales leads to actual sales of insurance policies; access to data from consumers and insurance carriers; accuracy of information provided from and to consumers during the insurance shopping process; cost-effective advertisement through internet search engines; ability to contact consumers and market products by telephone; global economic conditions, including inflation and tariffs; disruption to operations as a result of future acquisitions; significant estimates and assumptions in the preparation of our financial statements; impairment of goodwill; existing or potential litigation and other legal proceedings or inquiries, including the Department of Justice action alleging violations of the federal False Claims Act; our existing and future indebtedness; our ability to maintain compliance with our debt covenants; access to additional capital; failure to protect our intellectual property and our brand; fluctuations in our financial results caused by seasonality; accuracy and timeliness of commissions reports from insurance carriers; timing of insurance carriers’ approval and payment practices; factors that impact our estimate of the constrained lifetime value of commissions per policyholder; changes in accounting rules, tax legislation and other legislation; disruptions or failures of our technological infrastructure and platform; failure to maintain relationships with third-party service providers; cybersecurity breaches or other attacks involving our systems or those of our insurance carrier partners or third-party service providers; our ability to protect consumer information and other data; failure to market and sell Medicare plans effectively or in compliance with laws; and other factors related to our pharmacy business, including manufacturing or supply chain disruptions, access to and demand for prescription drugs, contractual reimbursement rates, and regulatory changes or other industry developments that may affect our pharmacy operations. For a further discussion of these and other risk factors that could impact our future results and performance, see the section entitled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended June 30, 2025 (the “Annual Report”) and subsequent periodic reports filed by us with the Securities and Exchange Commission. Accordingly, you should not place undue reliance on any such forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made, and, except as otherwise required by law, we do not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise..

About SelectQuote:

Founded in 1985, SelectQuote (NYSE: SLQT) pioneered the model of providing unbiased comparisons from multiple, highly-rated insurance companies, allowing consumers to choose the policy and terms that best meet their unique needs. Two foundational pillars underpin SelectQuote’s success: a strong force of highly-trained and skilled agents who provide a consultative needs analysis for every consumer, and proprietary technology that sources and routes high-quality leads. Today, the Company operates an ecosystem offering high touchpoints for consumers across insurance, pharmacy, and virtual care.

With an ecosystem offering engagement points for consumers across insurance, Medicare, pharmacy, and value-based care, the company now has three core business lines: SelectQuote Senior, SelectQuote Healthcare Services, and SelectQuote Life. SelectQuote Senior serves the needs of a demographic that sees around 10,000 people turn 65 each day with a range of Medicare Advantage and Medicare Supplement plans. SelectQuote Healthcare Services is comprised of the SelectRx Pharmacy, a Patient-Centered Pharmacy Home™ (PCPH) accredited pharmacy, SelectPatient Management, a provider of chronic care management services, and Healthcare Select which proactively connects consumers with a wide breadth of healthcare services supporting their needs.

Source: SelectQuote, Inc.

SELECTQUOTE, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands)

 

 

June 30, 2025

 

June 30, 2024

ASSETS

 

 

 

CURRENT ASSETS:

 

 

 

Cash, cash equivalents, and restricted cash

$

35,733

 

 

$

42,690

 

Accounts receivable, net of allowances of $11.8 million and $8.2 million, respectively

 

151,388

 

 

 

150,035

 

Commissions receivable-current

 

132,077

 

 

 

119,871

 

Other current assets

 

21,844

 

 

 

20,327

 

Total current assets

 

341,042

 

 

 

332,923

 

COMMISSIONS RECEIVABLE—Net

 

818,751

 

 

 

761,446

 

PROPERTY AND EQUIPMENT—Net

 

14,577

 

 

 

18,973

 

SOFTWARE—Net

 

15,060

 

 

 

13,978

 

OPERATING LEASE RIGHT-OF-USE ASSETS

 

24,635

 

 

 

23,437

 

INTANGIBLE ASSETS—Net

 

1,973

 

 

 

10,194

 

GOODWILL

 

29,438

 

 

 

29,438

 

OTHER ASSETS

 

3,880

 

 

 

3,519

 

TOTAL ASSETS

$

1,249,356

 

 

$

1,193,908

 

 

 

 

 

LIABILITIES, PREFERRED STOCK, AND SHAREHOLDERS’ EQUITY

 

 

 

CURRENT LIABILITIES:

 

 

 

Accounts payable

$

59,205

 

 

$

36,587

 

Accrued expenses

 

13,856

 

 

 

16,904

 

Accrued compensation and benefits

 

58,788

 

 

 

57,594

 

Operating lease liabilities—current

 

4,820

 

 

 

4,709

 

Current portion of long-term debt

 

68,523

 

 

 

45,854

 

Contract liabilities

 

698

 

 

 

8,066

 

Other current liabilities

 

7,020

 

 

 

4,873

 

Total current liabilities

 

212,910

 

 

 

174,587

 

LONG-TERM DEBT, NET—less current portion

 

316,589

 

 

 

637,480

 

DEFERRED INCOME TAXES

 

37,872

 

 

 

37,478

 

OPERATING LEASE LIABILITIES

 

25,982

 

 

 

25,685

 

OTHER LIABILITIES

 

80,485

 

 

 

1,877

 

Total liabilities

 

673,838

 

 

 

877,107

 

 

 

 

 

COMMITMENTS AND CONTINGENCIES

 

 

 

PREFERRED STOCK:

 

 

 

Senior Non-Convertible Preferred Stock, $0.01 par value, 350,000 shares and no shares issued and outstanding as of June 30, 2025 and June 30, 2024, respectively, current liquidation preference of $367.1 million and $0.0 million as of June 30, 2025 and June 30, 2024, respectively

 

224,374

 

 

 

 

SHAREHOLDERS’ EQUITY:

 

 

 

Common stock, $0.01 par value

 

1,728

 

 

 

1,694

 

Additional paid-in capital

 

571,605

 

 

 

580,764

 

Accumulated deficit

 

(222,189

)

 

 

(269,769

)

Accumulated other comprehensive income

 

 

 

 

4,112

 

Total shareholders’ equity

 

351,144

 

 

 

316,801

 

TOTAL LIABILITIES, PREFERRED STOCK, AND SHAREHOLDERS’ EQUITY

$

1,249,356

 

 

$

1,193,908

 

SELECTQUOTE, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(Unaudited)

(In thousands)

 

 

Three Months Ended June 30,

 

Year Ended June 30,

 

 

2025

 

 

 

2024

 

 

 

2025

 

 

 

2024

 

REVENUE:

 

 

 

 

 

 

 

Commissions and other services

$

134,503

 

 

$

165,656

 

 

$

797,841

 

 

$

856,923

 

Pharmacy

 

210,599

 

 

 

141,552

 

 

 

728,753

 

 

 

464,853

 

Total revenue

 

345,102

 

 

 

307,208

 

 

 

1,526,594

 

 

 

1,321,776

 

 

 

 

 

 

 

 

 

OPERATING COSTS AND EXPENSES:

 

 

 

 

 

 

 

Cost of commissions and other services revenue

 

58,844

 

 

 

64,548

 

 

 

305,127

 

 

 

318,798

 

Cost of goods sold—pharmacy revenue

 

182,312

 

 

 

120,644

 

 

 

630,340

 

 

 

405,004

 

Marketing and advertising

 

65,283

 

 

 

70,181

 

 

 

319,505

 

 

 

358,858

 

Selling, general, and administrative

 

9,594

 

 

 

43,993

 

 

 

164,442

 

 

 

141,042

 

Technical development

 

41,591

 

 

 

9,233

 

 

 

38,681

 

 

 

33,524

 

Total operating costs and expenses

 

357,624

 

 

 

308,599

 

 

 

1,458,095

 

 

 

1,257,226

 

 

 

 

 

 

 

 

 

INCOME (LOSS) FROM OPERATIONS

 

(12,522

)

 

 

(1,391

)

 

 

68,499

 

 

 

64,550

 

 

 

 

 

 

 

 

 

INTEREST EXPENSE, NET

 

(12,226

)

 

 

(23,409

)

 

 

(79,385

)

 

 

(93,551

)

CHANGE IN FAIR VALUE OF WARRANTS

 

34,181

 

 

 

 

 

 

59,525

 

 

 

 

OTHER EXPENSE, NET

 

(58

)

 

 

(15

)

 

 

(128

)

 

 

(65

)

INCOME (LOSS) BEFORE INCOME TAX EXPENSE (BENEFIT)

 

9,375

 

 

 

(24,815

)

 

 

48,511

 

 

 

(29,066

)

INCOME TAX EXPENSE (BENEFIT)

 

(3,493

)

 

 

6,202

 

 

 

931

 

 

 

5,059

 

 

 

 

 

 

 

 

 

NET INCOME (LOSS)

$

12,868

 

 

$

(31,017

)

 

$

47,580

 

 

$

(34,125

)

Senior Non-Convertible Preferred Stock accumulated dividends and accretion

$

(16,762

)

 

$

 

 

$

(22,548

)

 

$

 

NET INCOME (LOSS) ATTRIBUTABLE TO COMMON SHAREHOLDERS

$

(3,894

)

 

$

(31,017

)

 

$

25,032

 

 

$

(34,125

)

 

 

 

 

 

 

 

 

NET INCOME (LOSS) ATTRIBUTABLE TO COMMON SHAREHOLDERS PER SHARE:

 

 

 

 

 

 

 

Basic

$

(0.02

)

 

$

(0.18

)

 

$

0.14

 

 

$

(0.20

)

Diluted

$

(0.02

)

 

$

(0.18

)

 

$

0.01

 

 

$

(0.20

)

 

 

 

 

 

 

 

 

WEIGHTED-AVERAGE COMMON STOCK OUTSTANDING USED IN PER SHARE AMOUNTS:

 

 

 

 

 

 

 

Basic

 

184,201

 

 

 

169,204

 

 

 

176,148

 

 

 

168,519

 

Diluted

 

184,201

 

 

 

169,204

 

 

 

181,895

 

 

 

168,519

 

 

 

 

 

 

 

 

 

OTHER COMPREHENSIVE LOSS NET OF TAX:

 

 

 

 

 

 

 

Change in cash flow hedge

 

 

 

 

(2,364

)

 

 

(4,112

)

 

 

(9,567

)

OTHER COMPREHENSIVE LOSS

 

 

 

 

(2,364

)

 

 

(4,112

)

 

 

(9,567

)

COMPREHENSIVE INCOME (LOSS)

$

12,868

 

 

$

(33,381

)

 

$

43,468

 

 

$

(43,692

)

SELECTQUOTE, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)

 

 

Three Months Ended June 30,

 

Year Ended June 30,

 

 

2025

 

 

 

2024

 

 

 

2025

 

 

 

2024

 

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

 

 

 

Net income (loss)

$

12,868

 

 

$

(31,017

)

 

$

47,580

 

 

$

(34,125

)

Adjustments to reconcile net income (loss) to net cash, cash equivalents, and restricted cash used in operating activities:

 

 

 

 

 

 

 

Depreciation and amortization

 

4,876

 

 

 

6,407

 

 

 

20,460

 

 

 

24,998

 

Loss on disposal of property, equipment, and software

 

80

 

 

 

523

 

 

 

240

 

 

 

536

 

Impairment of long-lived assets

 

4,209

 

 

 

 

 

 

4,209

 

 

 

 

Share-based compensation expense

 

4,852

 

 

 

3,304

 

 

 

18,357

 

 

 

13,816

 

Deferred income taxes

 

(2,576

)

 

 

3,314

 

 

 

1,849

 

 

 

1,163

 

Amortization of debt issuance costs and debt discount

 

1,367

 

 

 

1,279

 

 

 

5,247

 

 

 

6,142

 

Write-off of debt issuance costs

 

 

 

 

 

 

 

93

 

 

 

293

 

Accrued interest payable in kind

 

713

 

 

 

5,254

 

 

 

14,013

 

 

 

19,577

 

Change in fair value of warrants

 

(34,181

)

 

 

 

 

 

(59,525

)

 

 

 

Non-cash lease expense

 

1,072

 

 

 

404

 

 

 

3,922

 

 

 

2,349

 

Bad debt expense

 

 

 

 

 

 

 

4,203

 

 

 

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

Accounts receivable, net

 

33,491

 

 

 

103,722

 

 

 

(5,555

)

 

 

5,203

 

Commissions receivable

 

(35,745

)

 

 

(48,194

)

 

 

(69,510

)

 

 

(40,819

)

Other assets

 

(5,938

)

 

 

653

 

 

 

(6,282

)

 

 

(1,967

)

Accounts payable and accrued expenses

 

(21,936

)

 

 

(28,726

)

 

 

19,226

 

 

 

7,347

 

Operating lease liabilities

 

(1,137

)

 

 

(1,095

)

 

 

(4,711

)

 

 

(4,897

)

Other liabilities

 

503

 

 

 

4,167

 

 

 

(5,482

)

 

 

15,620

 

Net cash provided by (used in) operating activities

 

(37,482

)

 

 

19,995

 

 

 

(11,666

)

 

 

15,236

 

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

 

 

 

Purchases of property and equipment

 

(501

)

 

 

(268

)

 

 

(2,191

)

 

 

(3,382

)

Proceeds from sales of property and equipment

 

 

 

 

 

 

 

 

 

 

253

 

Purchases of software and capitalized software development costs

 

(2,610

)

 

 

(2,219

)

 

 

(9,123

)

 

 

(8,284

)

Acquisition of business

 

 

 

 

(3,433

)

 

 

 

 

 

(3,433

)

Net cash used in investing activities

 

(3,111

)

 

 

(5,920

)

 

 

(11,314

)

 

 

(14,846

)

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

 

 

 

Proceeds from revolving line of credit

 

 

 

 

 

 

 

166,900

 

 

 

 

Payments on revolving line of credit

 

 

 

 

 

 

 

(166,900

)

 

 

 

Payments on Term Loans

 

(3,573

)

 

 

(8,471

)

 

 

(388,216

)

 

 

(38,883

)

Proceeds from ABS Notes

 

 

 

 

 

 

 

99,095

 

 

 

 

Payments on ABS Notes

 

(4,855

)

 

 

 

 

 

(16,577

)

 

 

 

Payments on other debt

 

(108

)

 

 

(37

)

 

 

(312

)

 

 

(149

)

Proceeds from common stock options exercised and employee stock purchase plan

 

(14

)

 

 

74

 

 

 

98

 

 

 

81

 

Proceeds from issuance of Senior Non-Convertible Preferred Stock

 

 

 

 

 

 

 

337,855

 

 

 

 

Senior Non-Convertible Preferred Stock issuance costs

 

 

 

 

 

 

 

(7,076

)

 

 

 

Payments of tax withholdings related to net share settlement of equity awards

 

(13

)

 

 

(1

)

 

 

(5,032

)

 

 

(374

)

Payments of debt issuance costs

 

 

 

 

(758

)

 

 

(2,479

)

 

 

(1,531

)

Net cash provided by (used in) financing activities

 

(8,563

)

 

 

(9,193

)

 

 

17,356

 

 

 

(40,856

)

NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH

 

(49,156

)

 

 

4,882

 

 

 

(5,624

)

 

 

(40,466

)

CASH, CASH EQUIVALENTS AND RESTRICTED CASH —Beginning of period

 

86,222

 

 

 

37,808

 

 

 

42,690

 

 

 

83,156

 

CASH, CASH EQUIVALENTS AND RESTRICTED CASH —End of period

$

37,066

 

 

$

42,690

 

 

$

37,066

 

 

$

42,690

 

SELECTQUOTE, INC. AND SUBSIDIARIES

Adjusted EBITDA to Income (Loss) before income tax expense (benefit) Reconciliation

(Unaudited)

 

 

Three Months Ended June 30, 2025

(in thousands)

Senior

 

Healthcare Services

 

Life

 

Total

Total revenue from reportable segments

$

82,464

 

 

$

214,028

 

 

$

47,984

 

 

$

344,476

 

Less:

 

 

 

 

 

 

 

Cost of commissions and other services revenue

 

(32,391

)

 

 

(5,536

)

 

 

(18,020

)

 

 

Cost of goods sold - pharmacy revenue

 

 

 

 

(180,988

)

 

 

 

 

 

Marketing expense

 

(41,752

)

 

 

(1,950

)

 

 

(22,813

)

 

 

Technical development

 

 

 

 

(495

)

 

 

 

 

 

Selling, general, and administrative

 

(599

)

 

 

(13,206

)

 

 

(229

)

 

 

Adjusted Segment EBITDA

 

7,722

 

 

 

11,853

 

 

 

6,922

 

 

 

26,497

 

Reconciliation of total segment Adjusted EBITDA

 

 

 

 

 

 

 

All other Adjusted EBITDA

 

 

 

 

 

 

 

950

 

Corporate

 

 

 

 

 

 

 

(24,753

)

Share-based compensation expense

 

 

 

 

 

 

 

(4,852

)

Transaction costs

 

 

 

 

 

 

 

(1,257

)

Depreciation and amortization

 

 

 

 

 

 

 

(4,876

)

Loss on disposal of property, equipment, and software, net

 

 

 

 

 

 

 

(80

)

Impairment of long-lived assets

 

 

 

 

 

 

 

(4,209

)

Change in fair value of warrants

 

 

 

 

 

 

 

34,181

 

Interest expense, net

 

 

 

 

 

 

 

(12,226

)

Income before income tax expense (benefit)

 

 

 

 

 

 

$

9,375

 

 

Three Months Ended June 30, 2024

(in thousands)

Senior

 

Healthcare Services

 

Life

 

Total

Total revenue from reportable segments

$

114,143

 

 

$

145,223

 

 

$

42,074

 

 

$

301,440

 

Less:

 

 

 

 

 

 

 

Cost of commissions and other services revenue

 

(37,534

)

 

 

(5,025

)

 

 

(15,287

)

 

 

Cost of goods sold - pharmacy revenue

 

 

 

 

(119,520

)

 

 

 

 

 

Marketing expense

 

(48,138

)

 

 

(1,700

)

 

 

(19,279

)

 

 

Technical development

 

 

 

 

(835

)

 

 

 

 

 

Selling, general, and administrative

 

(599

)

 

 

(17,234

)

 

 

(291

)

 

 

Adjusted Segment EBITDA

 

27,872

 

 

 

909

 

 

 

7,217

 

 

 

35,998

 

Reconciliation of total segment Adjusted EBITDA

 

 

 

 

 

 

 

All other Adjusted EBITDA

 

 

 

 

 

 

 

2,474

 

Corporate

 

 

 

 

 

 

 

(24,115

)

Share-based compensation expense

 

 

 

 

 

 

 

(3,304

)

Transaction costs

 

 

 

 

 

 

 

(5,529

)

Depreciation and amortization

 

 

 

 

 

 

 

(6,407

)

Loss on disposal of property, equipment, and software, net

 

 

 

 

 

 

 

(523

)

Interest expense, net

 

 

 

 

 

 

 

(23,409

)

Loss before income tax expense (benefit)

 

 

 

 

 

 

$

(24,815

)

SELECTQUOTE, INC. AND SUBSIDIARIES

Adjusted EBITDA to Income (Loss) before income tax expense (benefit) Reconciliation

(Unaudited)

 

 

Year Ended June 30, 2025

(in thousands)

Senior

 

Healthcare Services

 

Life

 

Total

Total revenue from reportable segments

$

600,393

 

 

$

742,705

 

 

$

172,978

 

 

$

1,516,076

 

Less:

 

 

 

 

 

 

 

Cost of commissions and other services revenue

 

(201,933

)

 

 

(25,163

)

 

 

(65,047

)

 

 

Cost of goods sold - pharmacy revenue

 

 

 

 

(625,389

)

 

 

 

 

 

Marketing expense

 

(234,335

)

 

 

(8,038

)

 

 

(80,269

)

 

 

Technical development

 

 

 

 

(2,187

)

 

 

 

 

 

Selling, general, and administrative

 

(2,454

)

 

 

(56,541

)

 

 

(993

)

 

 

Adjusted Segment EBITDA

 

161,671

 

 

 

25,387

 

 

 

26,669

 

 

 

213,727

 

Reconciliation of total segment Adjusted EBITDA

 

 

 

 

 

 

 

All other Adjusted EBITDA

 

 

 

 

 

 

 

10,597

 

Corporate

 

 

 

 

 

 

 

(98,070

)

Share-based compensation expense

 

 

 

 

 

 

 

(18,357

)

Transaction costs

 

 

 

 

 

 

 

(14,617

)

Depreciation and amortization

 

 

 

 

 

 

 

(20,460

)

Loss on disposal of property, equipment, and software, net

 

 

 

 

 

 

 

(240

)

Impairment of long-lived assets

 

 

 

 

 

 

 

(4,209

)

Change in fair value of warrants

 

 

 

 

 

 

 

59,525

 

Interest expense, net

 

 

 

 

 

 

 

(79,385

)

Income before income tax expense (benefit)

 

 

 

 

 

 

$

48,511

 

 

Year Ended June 30, 2024

(in thousands)

Senior

 

Healthcare Services

 

Life

 

Total

Total revenue from reportable segments

$

655,849

 

 

$

478,508

 

 

$

157,930

 

 

$

1,292,287

 

Less:

 

 

 

 

 

 

 

Cost of commissions and other services revenue

 

(216,348

)

 

 

(17,438

)

 

 

(60,017

)

 

 

Cost of goods sold - pharmacy revenue

 

 

 

 

(400,821

)

 

 

 

 

 

Marketing expense

 

(269,867

)

 

 

(6,260

)

 

 

(76,513

)

 

 

Technical development

 

 

 

 

(915

)

 

 

 

 

 

Selling, general, and administrative

 

(2,890

)

 

 

(45,253

)

 

 

(1,236

)

 

 

Adjusted Segment EBITDA

 

166,744

 

 

 

7,821

 

 

 

20,164

 

 

 

194,729

 

Reconciliation of total segment Adjusted EBITDA  

All other Adjusted EBITDA

 

 

 

 

 

 

 

14,127

 

Corporate

 

 

 

 

 

 

 

(91,863

)

Share-based compensation expense

 

 

 

 

 

 

 

(13,816

)

Transaction costs

 

 

 

 

 

 

 

(13,158

)

Depreciation and amortization

 

 

 

 

 

 

 

(24,998

)

Loss on disposal of property, equipment, and software, net

 

 

 

 

 

 

 

(536

)

Interest expense, net

 

 

 

 

 

 

 

(93,551

)

Loss before income tax expense (benefit)

 

 

 

 

 

 

$

(29,066

)

 

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.